125 related articles for article (PubMed ID: 29629977)
21. Characterization of MED12, HMGA2, and FH alterations reveals molecular variability in uterine smooth muscle tumors.
Mäkinen N; Kämpjärvi K; Frizzell N; Bützow R; Vahteristo P
Mol Cancer; 2017 Jun; 16(1):101. PubMed ID: 28592321
[TBL] [Abstract][Full Text] [Related]
22. Missense mutations in exon 2 of the MED12 gene are involved in IGF-2 overexpression in uterine leiomyoma.
Di Tommaso S; Tinelli A; Malvasi A; Massari S
Mol Hum Reprod; 2014 Oct; 20(10):1009-15. PubMed ID: 25015674
[TBL] [Abstract][Full Text] [Related]
23. Deep sequencing reveals the molecular pathology characteristics between primary uterine leiomyoma and pulmonary benign metastasizing leiomyoma.
Jiang J; He M; Hu X; Ni C; Yang L
Clin Transl Oncol; 2018 Aug; 20(8):1080-1086. PubMed ID: 29484624
[TBL] [Abstract][Full Text] [Related]
24. Factors targeting
Bullerdiek J; Rommel B
F1000Res; 2018; 7():359. PubMed ID: 30647905
[TBL] [Abstract][Full Text] [Related]
25. Prevalence of MED12 mutations in uterine and extrauterine smooth muscle tumours.
Matsubara A; Sekine S; Yoshida M; Yoshida A; Taniguchi H; Kushima R; Tsuda H; Kanai Y
Histopathology; 2013 Mar; 62(4):657-61. PubMed ID: 23347103
[TBL] [Abstract][Full Text] [Related]
26. Factors affecting the loss of MED12-mutated leiomyoma cells during in vitro growth.
Bloch J; Holzmann C; Koczan D; Helmke BM; Bullerdiek J
Oncotarget; 2017 May; 8(21):34762-34772. PubMed ID: 28410233
[TBL] [Abstract][Full Text] [Related]
27. Frequency and Spectrum of MED12 Exon 2 Mutations in Multiple Versus Solitary Uterine Leiomyomas From Russian Patients.
Osinovskaya NS; Malysheva OV; Shved NY; Ivashchenko TE; Sultanov IY; Efimova OA; Yarmolinskaya MI; Bezhenar VF; Baranov VS
Int J Gynecol Pathol; 2016 Nov; 35(6):509-515. PubMed ID: 26630226
[TBL] [Abstract][Full Text] [Related]
28. MED12 somatic mutations in fibroadenomas and phyllodes tumours of the breast.
Piscuoglio S; Murray M; Fusco N; Marchiò C; Loo FL; Martelotto LG; Schultheis AM; Akram M; Weigelt B; Brogi E; Reis-Filho JS
Histopathology; 2015 Nov; 67(5):719-29. PubMed ID: 25855048
[TBL] [Abstract][Full Text] [Related]
29. Selective genetic analysis of myoma pseudocapsule and potential biological impact on uterine fibroid medical therapy.
Di Tommaso S; Massari S; Malvasi A; Vergara D; Maffia M; Greco M; Tinelli A
Expert Opin Ther Targets; 2015 Jan; 19(1):7-12. PubMed ID: 25363374
[TBL] [Abstract][Full Text] [Related]
30. Expression of erythropoietin messenger ribonucleic acid in wild-type MED12 uterine leiomyomas under estrogenic influence: new insights into related growth disparities.
Asano R; Asai-Sato M; Matsukuma S; Mizushima T; Taguri M; Yoshihara M; Inada M; Fukui A; Suzuki Y; Miyagi Y; Miyagi E
Fertil Steril; 2019 Jan; 111(1):178-185. PubMed ID: 30554729
[TBL] [Abstract][Full Text] [Related]
31. Mutation status of the mediator complex subunit 12 (MED12) in uterine leiomyomas and concurrent/metachronous multifocal peritoneal smooth muscle nodules (leiomyomatosis peritonealis disseminata).
Rieker RJ; Agaimy A; Moskalev EA; Hebele S; Hein A; Mehlhorn G; Beckmann MW; Hartmann A; Haller F
Pathology; 2013 Jun; 45(4):388-92. PubMed ID: 23635816
[TBL] [Abstract][Full Text] [Related]
32. HMGA2 and MED12 alterations frequently co-occur in uterine leiomyomas.
Galindo LJ; Hernández-Beeftink T; Salas A; Jung Y; Reyes R; de Oca FM; Hernández M; Almeida TA
Gynecol Oncol; 2018 Sep; 150(3):562-568. PubMed ID: 30017537
[TBL] [Abstract][Full Text] [Related]
33. Exome sequencing identifies highly recurrent MED12 somatic mutations in breast fibroadenoma.
Lim WK; Ong CK; Tan J; Thike AA; Ng CC; Rajasegaran V; Myint SS; Nagarajan S; Nasir ND; McPherson JR; Cutcutache I; Poore G; Tay ST; Ooi WS; Tan VK; Hartman M; Ong KW; Tan BK; Rozen SG; Tan PH; Tan P; Teh BT
Nat Genet; 2014 Aug; 46(8):877-80. PubMed ID: 25038752
[TBL] [Abstract][Full Text] [Related]
34. Primary osteosarcoma of the uterus: report of a case with immunohistochemical analysis.
Emoto M; Iwasaki H; Kawarabayashi T; Egami D; Yoshitake H; Kikuchi M; Shirakawa K
Gynecol Oncol; 1994 Sep; 54(3):385-8. PubMed ID: 8088619
[TBL] [Abstract][Full Text] [Related]
35. CYP24A1 expression analysis in uterine leiomyoma regarding MED12 mutation profile.
Fazeli E; Piltan S; Gholami M; Akbari M; Falahati Z; Yassaee F; Sadeghi H; Mirfakhraie R
Arch Gynecol Obstet; 2021 Mar; 303(3):787-792. PubMed ID: 33025089
[TBL] [Abstract][Full Text] [Related]
36. MED12 mutations in uterine fibroids--their relationship to cytogenetic subgroups.
Markowski DN; Bartnitzke S; Löning T; Drieschner N; Helmke BM; Bullerdiek J
Int J Cancer; 2012 Oct; 131(7):1528-36. PubMed ID: 22223266
[TBL] [Abstract][Full Text] [Related]
37. Genomics of uterine leiomyomas: insights from high-throughput sequencing.
Mehine M; Mäkinen N; Heinonen HR; Aaltonen LA; Vahteristo P
Fertil Steril; 2014 Sep; 102(3):621-9. PubMed ID: 25106763
[TBL] [Abstract][Full Text] [Related]
38. Catechol-O-methyltransferase Val158Met polymorphism is associated with increased risk of multiple uterine leiomyomas either positive or negative for
Dzhemlikhanova LK; Efimova OA; Osinovskaya NS; Parfenyev SE; Niauri DA; Sultanov IY; Malysheva OV; Pendina AA; Shved NY; Ivashchenko TE; Yarmolinskaya MI; Kakhiani MI; Gorovaya EA; Tkachenko AN; Baranov VS
J Clin Pathol; 2017 Mar; 70(3):233-236. PubMed ID: 27491313
[TBL] [Abstract][Full Text] [Related]
39. Frequency of MED12 Mutation in Relation to Tumor and Patient's Clinical Characteristics: a Meta-analysis.
He C; Nelson W; Li H; Xu YD; Dai XJ; Wang YX; Ding YB; Li YP; Li T
Reprod Sci; 2022 Feb; 29(2):357-365. PubMed ID: 33569750
[TBL] [Abstract][Full Text] [Related]
40. Primary osteosarcoma of the uterine corpus: case report and review of the literature.
Su M; Tokairin T; Nishikawa Y; Yoshioka T; Takahashi O; Watanabe H; Doi Y; Omori Y; Yoshioka T; Sageshima M; Tanaka T; Enomoto K
Pathol Int; 2002 Feb; 52(2):158-63. PubMed ID: 11940222
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
